PainTEQ Highlights CMS 2027 Physician Fee Schedule Establishes Non-Facility (Office) Payment Rate for CPT Code 27279

Starting January 1, 2027, CMS will set a national non-facility office payment rate of approximately $19,441 for CPT code 27279, which previously had no office rate. The change creates a Medicare payment pathway for eligible office-based procedures, but does not establish coverage; coverage remains subject to applicable payer policies and medical-necessity requirements. Hospital outpatient and ambulatory surgery center rates also rise, while physician fees for facility procedures decrease modestly.

Analysis

This is a reimbursement-enablement signal, not proof of incremental demand: a payment rate does not establish coverage, and local Medicare contractor policies and prior authorization remain the gating variables. The key economic question is whether enough MACs permit office-based 27279 procedures for practices to invest in the equipment, staffing, and workflows required to shift cases out of hospitals and ASCs.

If coverage and office economics align, PainTEQ’s TRAQ may gain an adoption advantage, while hospitals and ASCs could lose some case volume. The spillover to other device makers, including SI-BONE, depends on whether their products and procedures fit the code and can be performed economically in office settings; verify before attributing a revenue opportunity. The lower facility physician fee may also modestly offset site-of-service savings for physicians.

Over the next 1–3 months, watch for MAC policy updates, payer authorization guidance, and practice-level implementation—not the headline payment amount alone. From 2027 onward, actual claims and site-of-service mix will determine whether this becomes a meaningful structural channel. Reversals could come from restrictive coverage, denials, safety or utilization scrutiny, or office costs that make the shift uneconomic. The release is from a private company, so there is no direct public-equity expression; the likely market read-through to listed device peers is too conditional for a trade today.

Key Decisions for Investors

• No immediate trade: the payment pathway is not equivalent to coverage, and PainTEQ is not a direct public-equity vehicle.
• Set a 2027 watch item for MAC coverage and prior-authorization changes, followed by office-based 27279 claims and procedure site-of-service mix; these are the evidence needed to validate adoption.
• Monitor SI-BONE and other SI-joint device makers for product/code fit and any disclosure of office-channel exposure. Do not treat the payment announcement alone as a sector-wide earnings catalyst.
• Falsification trigger: restrictive MAC decisions, persistent denials, or limited office migration after January 1 would undermine the adoption thesis; broad coverage and sustained office utilization would strengthen it.